DRUG MEXC RealStocks
Own real DRUG shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 07:39:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Bright Minds Biosciences Inc. (DRUG) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $20.63, with a market capitalization of $202.31M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $17.40 to $123.75. This page covers its latest market performance, valuation, price trends and company information.
$202.31M | |
$20.83 | |
$21.65 | |
$20.42 | |
$20.51 | |
126.58K | |
174.49K | |
-- | |
$123.75 | |
$17.40 | |
-- | |
2026-06-30 |
Bright Minds Biosciences Inc. (DRUG) last closed at $20.63 as of 2026-11-19 00:31:00, up 1.07% ($0.22) from the previous close of $20.51.
During the latest regular trading session, DRUG traded between $20.42 and $21.65, with a volume of 126.58K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Bright Minds Biosciences Inc. (DRUG) moved from $22.61 to $20.63, representing a decline of 8.77% ($1.98).
The stock traded between $19.86 and $24.99 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 156.97 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3.0%
DRUG is currently trading at $20.63, placing it 3.0% of the way from its 52-week low of $17.40 to its 52-week high of $123.75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
| Employees | 25 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Bright Minds Biosciences Inc. (DRUG) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to DRUG, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between DRUG shares and USD.
DRUG Shares to USD
1.00 DRUG shares = 20.627 USD
Calculations are estimates based on the latest available price and are for reference only.